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Objectives: Children with severe acute malnutrition (SAM) are treated with empiric amoxicillin or
penicillin and gentamicin because of the high risk of severe infections. Experts have suggested, based on
available evidence, adding metronidazole to cover anaerobic bacteraemia and diarrhoea caused by
Giardia duodenalis or Clostridium difficile. The objective of this study was to assess the importance of
these infections in children with SAM.
Methods: Children from 6 months to 15 years with SAM were enrolled and followed clinically. Aerobic
and, when patient weight permitted, anaerobic blood cultures were done using Bactec® system, and
isolates identified with matrix-assisted laser desorption ionizationetime of flight mass spectrometry.
Stool samples were tested for C. difficile, G. duodenalis and Entamoeba histolytica by PCR.
Results: A total of 334 children were enrolled and 174 out of 331 (53%) for which data on this was
available had diarrhoea. Of 273 patients tested by blood culture, 11 had bacteraemia (4.0%, 95% CI 2.3
e7.1%) but none with strict anaerobic bacteria (0/153, 95% CI 0e2.4%). There was no difference in the
prevalence of C. difficile between children with (5/128, 4%) and without (7/87, 8%) diarrhoea (OR 0.47, 95%
CI 0.14e1.53), and no difference in the prevalence of Giardia between these groups (78/138, 60% vs. 46/87,
53%; OR 1.34, 95% CI 0.77e2.32). Children with C. difficile had higher mortality than those without this
infection (3/11, 27%, vs. 7/186, 4%; OR 43, 95% CI 3.9e483).
Conclusion: Our results do not provide support for empiric metronidazole to cover for anaerobic
bacteraemia. Trials evaluating the effect of empiric treatment and its effect on G. duodenalis and C. difficile
are warranted. M. Zangenberg, Clin Microbiol Infect 2020;26:255.e7e255.e11
© 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Infections are a common cause of death in children with severe
acute malnutrition (SAM). According to one review, the average
prevalence of bacteraemia among children with SAM is 17% [1], butfor Medical Parasitology,
ity of Copenhagen, Denmark.
angenberg).
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).more recent studies found a lower prevalence of around 5% [2,3].
Themost common causes of bacteraemia among childrenwith SAM
are Salmonella, Escherichia coli, Staphylococcus aureus and Strepto-
coccus pneumoniae [4,5]. Children with SAM are treated with
antibiotics empirically: hospitalized cases with parenteral peni-
cillin and gentamicin and outpatients with oral amoxicillin [6].
The rationale for empiric systemic antibiotics is the high risk of
infections and non-specific symptoms of sepsis in SAM, and the
limited microbiology laboratory capacity in places where SAM is
common [7]. Evenwith the current empiric antibiotic regimens, theof Clinical Microbiology and Infectious Diseases. This is an open access article under
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[8]. Experts have suggested adding empiric metronidazole to cover
for possible anaerobic bacteraemia [9e11], although its prevalence
has not been assessed in this patient group.
Some authors also argue that the risk of gastro-intestinal
infection with C. difficile or G. duodenalis justifies the use of
empiric metronidazole treatment in children with SAM [10,12].
However, the prevalence of C. difficile and its relevance in SAM,
particularly among children below the age of 1 year [13], is un-
known. While G. duodenalis is commonly found in stool samples
from children with SAM, its contribution to morbidity and mor-
tality is controversial [14e16].
The objective of this study was to determine the aetiology of
bacteraemia, including anaerobes, and to assess the prevalence
of the metronidazole-sensitive enteropathogens G. duodenalis,
C. difficile and Entamoeba histolytica in children with SAM. Further-
more, we wished to relate these findings to severity of disease and
clinical outcome.
Methods
Study design and participants
This was a prospective observational study, implemented in three
sites in Ethiopia: Jimma University Specialized Teaching Hospital
(JUSTH), Serbo Health Centre (SHC) and the Missionary of Charity
Clinic (MiCC). The parent study was designed to evaluate the useful-
ness of clinical algorithms for determining bacteraemia and treatment
outcome. Enrolment started at JUSTH in June 2016, at SHC in February
2017 andMiCC in June 2017 andwas completed inMay 2018. Children
with SAM between 6 months and 15 years of age, seeking healthcare
at one of the three siteswere enrolled after seeing the clinical staff and
giving consent, but before any treatment was started.
The definition of SAMwas one or more of the following: weight
for height <70% of the median of the National Center for Health
Statistics (NCHS) reference curve, mid-upper arm circumference
(MUAC) < 115 mm and the presence of bilateral oedema. Besides
nutritional therapy, including essential vitamins and supportive
care, the children received empiric antibiotic treatment with
amoxicillin (50e100 mg/kg/day) and if hospitalized gentamicin
(5 mg/kg/day) was added.
Data collection
Demographic and clinical data were collected by research
nurses using standardized case report forms. We collected details
on treatment and outcomes from follow-up visits during admission
and from the hospital medical records.
Specimen collection
Before treatment was started, we collected a venous blood
sample aseptically. The amount of blood was based on the child's
weight and total blood volume [17]. First, an EDTA plasma tube
(Vacuette, BectonDickinson, Vienna, Austria), a Serum Sep Clot tube
(Vacuette) and one aerobic blood culture vial (BACTEC Peds Plus/F
medium, Becton Dickinson) were obtained. For patient safety, we
limited the number of blood samples from the smallest children and
prioritized blood samples for blood count, biochemistry and an
aerobic blood culture. From children above 7 kg we collected
one additional anaerobic blood culture vial (BACTEC Lytic/10
Anaerobic/F).We supplementedwith one aerobic vial from children
weighing more than 9 kg and two aerobic vials from children above
11 kg. The bottles were weighed before and after blood collection
(Sartorius TE412, JUSTH and EatSmart ESKS, MiCC and SHC).Stool samples were collected using plastic-lined diapers and
transferred to a collection tube or directly in the tube. When
feasible, stool samples were collected before treatment was started,
but treatment was not delayed if a stool sample could not be
obtained immediately.
Samples were immediately brought to the research laboratories
in JUTSH whereas in SHC and MiCH tubes for biochemistry and
stool samples were kept at 4C and blood cultures were kept at
ambient temperature (<8 hr) until transported to JUSTH, once daily.
Laboratory methods
We used an automated blood culture system (BACTEC FX40,
Becton Dickinson, Baltimore, MD, USA) to incubate the blood cul-
tures and a few drops were aspirated from bottles flagged as pos-
itive for subculture on agar plates. From aerobic bottles subculture
was done on chocolate agar in a humidified atmosphere with 5%
CO2, from anaerobic bottles in addition on chocolate agar in
O2-depleted atmosphere using incubation containers with sachets
creating an anaerobic environment (GasPak EZ anaerobe container
system sachets, Becton Dickinson). The positive samples were
analysed in the local microbiology laboratory and the results of the
identification and susceptibility testing were immediately reported
to the clinical staff. Isolates were frozen at e80 in a skimmedmilk,
tryptone, glucose, glycerol transport medium and sent to Depart-
ment of Clinical Microbiology, Rigshospitalet, Denmark. After
re-culture on agar plates the isolates were identified using matrix-
assisted laser desorption ionizationetime of flight (MALDI-TOF)
mass spectrometry (Microflex, Bruker, Bremen, Germany). If iden-
tificationwas not possiblewe performed real-time PCR (LightCycler
480, Roche, Basel, Switzerland), sequenced the PCR products (GATC,
Eurofins, Hamburg, Germany) and aligned to standard databases
(SepsiTest BLAST and NCBI BLAST). Antimicrobial susceptibility
testing (AST) was conducted by disc diffusion (Oxoid, Basingstoke,
UK) and with gradient minimum inhibitory concentration (MIC)
strips (Etest, bioMerieux SA, Paris, France). AST procedures and
interpretation was done according to EUCAST guidelines [18].
The Department of Clinical Immunology in the Rigshospitalet,
Copenhagen, screened the serum samples for HIV using Vitros anti-
HIV1þ2 Enzyme Immunoassay (Ortho Clinical Diagnostics, Penc-
oed, Bridgend, UK) and confirmatory testing using INNO-LIA HIV I/II
Score (Fujirebio Europe, Gent, Belgium).
Stool samples were frozen at e80C, shipped to Denmark and
tested with the C. difficile assay and ‘Enteric Parasite Panel’ (EPP) on
the BD MAX platform (Becton Dickinson). The tests detect nucleic
acids for the C. difficile toxin B gene and from G. duodenalis and
E. histolytica, respectively (BD MAX Cdiff assay and BD MAX
EPP, Becton Dickinson, Canada). If results were unresolved due to
inhibitory specimen or reagent failure, analyses were repeated, if
necessary, after diluting the stool samples in S.T.A.R. buffer (Roche)
to counteract PCR inhibition.
We analysed the complete blood count using an automated
haematology analyser (KX-21 N, Sysmex Corporation, Bellport, NY,
USA).
Definitions
We defined growth of an organism known to cause bacteraemia
in children as a ‘pathogen’. Gram-positive rods (with specific
exceptions that were not encountered), coagulase negative staph-
ylococci (CoNS) or non-beta haemolytic streptococci were defined
as ‘likely contaminants’ if they grew in a single blood culture bottle,
and as ‘possible contaminants’ if they grew in two or more bottles
obtained from the same venepuncture from the same patient.
We used a standard definition of medical complications [6,19].
Table 2
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SAM or were undergoing treatment with no further follow-up data
available after 4 weeks of treatment, they were categorized as
having ‘likely treatment failure’.
Statistical methods
We used EpiData 3.1 (EpiData, Odense, Denmark) to enter and
validate data and SAS Enterprise Guide, Version 7.11 of the SAS
System for Windows (SAS Institute Inc., Cary, NC, USA) for data
analysis. A p-value < 0.05 was considered statistically significant
and 95% confidence intervals (CI) were used. While the NCHS
reference curve were used to identify children with SAM, the
weight for height/length z-score (WHZ) based on WHO standard
curves for children 6months to 5 years and bodymass index for age
for children 5e15 years were used to present the data [20]. We used
mixed linear or logistic regression models, both with random ef-
fects for site. We assessed weight gain by measuring the first
oedema-free weight, and repeated weight measures during treat-
ment and on discharge from the health facility. To assess the effect
of relevant variables on weight gain, we used a mixed model linear
regression analysis, with a Gaussian covariance structure for
repeated measurements and random effects for site.
Ethical issues
The study was approved by Jimma University Institutional Re-
view Board (Reference HRPGC/239/2015) and the Ethiopian
National Research Ethics Review Committee (Reference 310/285/
2017) and received consultative approval by the Danish National
Committee on Health Research Ethics (Reference 1800407). After
obtaining written informed consent from caregivers the children
were considered eligible.
Results
Of 343 children screened, 334 (97%) were enrolled in the study.
The majority of children (92%, 306/334) were treated as inpatients,
although 46% (154/333) did not have any medical complications
and could potentially have been treated as outpatients. One child
died before clinical data were collected. Fifty-three per cent (174 of
331 for whom data was available) had diarrhoea. Sixteen per cent
(50/310) had received antibiotics in the week prior to enrolment
but none reported having receivedmetronidazole (Table 1). Data onTable 1
Background characteristics of the enrolled children
na Value
Female sex, % (n) 333 48 (160)
Age, months 333 33.0 (14.0; 60.0)b
>59, % (n) 333 27 (90)
Mid-upper arm circumference 332 117 (19)c




In children without oedema 87 e3.8 (1.1)c
BMI for age (5e14 years)d 29 e4.0 (1.9)c
Bilateral oedema 333 63% (215)
Medical complications 333 54% (179)
Diarrhoea 331 53% (174)
Caregiver-reported fever 330 28% (94)
Treatment for malnutrition during the last week 282 9% (24)
Treatment with antibiotics during the last week 310 16% (50)
a Number of children for whom data were available.
b Median (25th; 75th percentiles).
c Mean (standard deviation).
d WHO z-scores.treatment outcome were available for 283 out of 334 (85%) of
whom 17 (6%) died and another 57 (20%) had other kinds of
treatment failure. None of the children had HIV.
Blood cultures
Of the 334 children enrolled, 273 (82%) children had at least one
aerobic blood culture drawn and 153 (46%) an anaerobic blood
culture. Of the 120 children for whom an anaerobic blood culture
was missing, 103 (86%) weighed less than 7 kg and were therefore
not eligible for more than an aerobic blood culture.
We did not find any strict anaerobic bacteria (95% CI 0e2.4%).
More specifically, we did not find any metronidazole-sensitive
organisms that are commonly insensitive to routine treatment
with penicillin such as Bacteroides spp. Ten per cent (27/273) of the
patients had a positive blood culture with any organism and a
pathogenic bacteriumwas detected in 4% (11/273, 95% CI 2.3e7.1%)
(Table 2). Twenty-three had growth of a single organism and four
had growth of two organisms. Of the 17 patients with suspected
contaminants (one had both a contaminant and a pathogen), 15
were likely contaminants and the remaining two possible
contaminants. The median blood volume cultured was 1.17 mL (IQR
1.00e2.00) for the first aerobic bottle and 1.95 mL (IQR 1.00e3.00)
for the anaerobic bottle.
We did not find a high level of resistance among the bacterial
isolates (Table S1).
Follow-up data were available for 233 of the 273 childrenwith a
blood culture (85%). Of the children with a pathogen in their blood
three out of ten (30%) died, while seven out of 207 (3%) of the
children with negative blood cultures died (OR 12, 95% CI 2.6e58).
Two of 12 (17%) children with growth of a suspected contaminant
died as opposed to the seven out of 207 (3%) with a negative blood
culture, (OR 7.5, 95% CI 1.3e45). Adjusting for medical complica-
tions, oedema and age had no significant effect on this mortality
estimate (Table S2). Bacteraemia was not associated with axillary
temperature, leucocyte count, pulse rate or respiratory rate





















a Four children had growth of two different bacteria. One
child had both Streptococcus pneumoniae and Escherichia coli,
one child had a pathogen and a likely contaminant, and two
children had two different contaminants.
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G. duodenalis
A stool sample was collected from 218 (65%) of the children and
follow-up data were available from 198 (91%) of these. Presence of
G. duodenalis was common (124/218, 57%) and we did not find an
association between G. duodenalis and diarrhoea; 60% (78/138) of
children with diarrhoea and 53% (46/87) without diarrhoea had
G. duodenalis in their stool (OR 1.34, 95% CI 0.77e2.32) (Table 3).
The children with G. duodenalis were younger, weighed less at
enrolment and had bilateral oedema more frequently (Table S3).
There was no difference in weight gain between children with and
without presence of G. duodenalis and it was not associated with
treatment failure or mortality (Table S3).
C. difficile
Of the 216 children with a stool sample tested for C. difficile, 27
(13%) were below 12 months of age. We detected DNA from
toxigenic C. difficile in 12 out of 216 (6%) children, and we did not
find any difference in the prevalence between childrenwith (5/128,
4%) and children without (7/87, 8%) diarrhoea (OR 0.47, 95% CI
0.14e1.53). Presence of C. difficile was associated with mortality as
27% (3/11) with C. difficile died compared with 4% (7/186) of the
children without this infection (OR 43, 95% CI 3.9e483, adjusted
for age, diarrhoea, admission weight, bilateral oedema, history of
antibiotics and medical complications (Table 3 and Table S4).
Excluding children below 12 months from the analysis gave similar
results (Table S4). C. difficile was not associated with admission
weight or weight gain during follow-up (Table S4).
E. histolytica
None of the samples contained DNA of E. histolytica (0%, 95% CI
0e1.7%) (Table 3).
Discussion
Wedid not find any cases with bacteraemiawith strict anaerobic
bacteria. While G. duodenaliswas common in the stool samples, the
presence of G. duodenalis was not associated with diarrhoea. Pres-
ence of C. difficile was not associated with diarrhoea, but children
with C. difficile in their stool had a higher mortality than children
without this infection.
Our study has several limitations. First, our sample size was
relatively small, since we did not collect an anaerobic blood culture
from children below 7 kg due to patient safety. Furthermore, the
median blood volume for the anaerobic bottle was lower than the
recommended 3 mL and we cannot rule out false-negative tests.
Furthermore, the history of metronidazole use prior to admission
was based on caregiver recall and could have been underestimated.Table 3
















n total/n % n total/n % n total/n % n total/n %
G. duodenalis 124/218 57 78/130 60 46/87 53 3/114 3
C. difficile 12/216a 6 5/128 4 7/87 8 3/11 27c
E. histolytica 0/2171 0 0/129 0 0/87 0 N/A N/A
a Analysis for C. difficilewas not possible for two cases and for E. histolytica for one
case.
b Data on diarrhoea missing for one case.
c Presence of C. difficile was associated with mortality.Thus, larger studies are needed to formally exclude a major role of
anaerobic bacteraemia in patients with SAM. Small intestinal
bacterial overgrowth (SIBO) has been proposed as an argument for
metronidazole in SAM.We did not examine this possibility, since the
connection between SIBO and SAM is speculative, and the evidence
for treating SIBO with metronidazole is limited [21]. Lastly, our
findingsmight be less relevant for settingswith highHIVprevalence,
although even among HIV-positive children with SAM the clinical
evidence for empiric metronidazole use is uncertain [10].
We found no cases with strict anaerobic bacteraemia. While
there are no studies on childrenwith SAM for comparison, previous
studies among paediatric patients without acute malnutrition have
given similar results. A study among paediatric oncology patients
did not find any clinically significant infections with anaerobes [22]
and a study reviewing data from a paediatric emergency depart-
ment found strict anaerobes in only 0.05% of the samples [23]. We
found bacteraemia with a known pathogen in 4% of the children
which tallies with recent studies in childrenwith SAM [2,24]. Some
previous studies that found a considerably higher prevalence of
bacteraemia either only included children with medical complica-
tions in addition to SAM [25] or were conducted in settings with
high HIV prevalence [26]. We tried to ensure a strict aseptic blood
collection procedure and had lower rate of cultures with suspected
contaminants than similar studies [27,28]. The children with sus-
pected contaminants had significantly increased mortality. Thus, it
is possible that some of the suspected contaminants were true
infections and could play a pathogenic role in children with SAM.
This has also been suggested in studies of neonatal sepsis [29].
Bacteraemia was not associated with axillary temperature, leuco-
cyte count, pulse rate or respiratory rate, confirming that diagnosis
of invasive infection in children with SAM is challenging without
blood cultures.
Two studies among children with SAM, using PCR, reported a
prevalence of Giardia of 33% and 38%, respectively [14,15], which is
in line with our findings. The lack of association between Giardia
and diarrhoea in our study might be due to lack of power, but our
finding is in line with several studies, some of which reported
higher detection rates of Giardia among non-diarrhoeal controls
than among children with diarrhoea [16,30]. Previous studies also
failed to find an association between G. duodenalis and clinical
outcome among children with SAM [14,15]. This questions the
relevance of diagnosing children with SAM for G. duodenalis.
An association between C. difficile and mortality has previously
been reported in children without SAM [31]. We are, however, not
able to conclude anything on causality and our finding might be
confounded bymore frequent use of antibiotics among the severely
ill patients. One previous study assessed the rate C. difficile infection
in children with SAM but failed to find any cases [14]. While it is
currently not recommended to test children below 12 months
because asymptomatic carriage is thought to be common, a study
found that 26% of all children hospitalized with symptomatic
C. difficile infection were below 1 year of age [13]. More research is
needed in this area, especially among children with SAM, in whom
the relevance of infectionwith C. difficile among children below the
age of 1 year is unknown.
Infection with E. histolytica was previously thought to be a
common cause of childhood diarrhoea [32]. Several recent studies
also found no or very few infections by PCR, suggesting that
microscopy, which was used in earlier studies, might have over-
estimated its incidence [16,33].
Conclusion
Taken together, our data do not provide support for the general
use of metronidazole in children with SAM. G. duodenalis was
M. Zangenberg et al. / Clinical Microbiology and Infection 26 (2020) 255.e7e255.e11 255.e11common among children without diarrhoea and treatment of
asymptomatic C. difficile and G. duodenalis infections remain
controversial, particularly in young children [34]. We suggest that
future clinical trials of metronidazole use in children with SAM
should include molecular testing for G. duodenalis and C. difficile to
stratify for treatment effects on these organisms. Anaerobic blood
culture may be redundant for diagnosing bacteraemia in children
with SAM.
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